Abstract
BackgroundThe anti-tumor necrosis factor (TNF) agents adalimumab (ADA), certolizumab pegol (CZP), and etanercept (ETN) are approved in Europe for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA). The efficacy of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have